News
DVA
137.64
-2.27%
-3.19
Weekly Report: what happened at DVA last week (0202-0206)?
Weekly Report · 22h ago
DaVita Stock: Is Wall Street Bullish or Bearish?
Barchart · 1d ago
2 Warren Buffett Stocks to Buy Hand Over Fist in 2026 and 1 to Avoid
The Motley Fool · 1d ago
The 5 Most Interesting Analyst Questions From DaVita’s Q4 Earnings Call
Barchart · 1d ago
A Look At DaVita (DVA) Valuation After 2025 Earnings And Share Buybacks
Simply Wall St · 1d ago
Notable healthcare headlines for the week: Pfizer Novo Nordisk in focus
Seeking Alpha · 1d ago
DaVita (DVA) Is Up 28.8% After Strong 2026 Guidance And Heavy Buybacks - What's Changed
Simply Wall St · 2d ago
What Moved Markets This Week
Seeking Alpha · 2d ago
Even With A 30% Surge, Cautious Investors Are Not Rewarding DaVita Inc.'s (NYSE:DVA) Performance Completely
Simply Wall St · 3d ago
DaVita price target raised to $158 from $128 at Truist
TipRanks · 4d ago
Before Retiring, Warren Buffett Sold These 6 Stocks and Piled Into This High-Yield Investment
NASDAQ · 4d ago
DaVita (DVA) Margin Compression To 5.3% Challenges Bullish Valuation Narratives
Simply Wall St · 5d ago
DaVita Is Maintained at Buy by UBS
Dow Jones · 5d ago
DaVita Price Target Raised to $190.00/Share From $186.00 by UBS
Dow Jones · 5d ago
UBS Maintains Buy on DaVita, Raises Price Target to $190
Benzinga · 5d ago
DaVita (DVA) Q1 2025 Earnings Call Transcript
The Motley Fool · 5d ago
DaVita (DVA) Q2 2025 Earnings Call Transcript
The Motley Fool · 5d ago
DaVita (DVA) Q3 2024 Earnings Call Transcript
The Motley Fool · 5d ago
DaVita price target raised to $144 from $133 at TD Cowen
TipRanks · 5d ago
Analysts Offer Insights on Healthcare Companies: DaVita (DVA) and Immunocore Holdings (IMCR)
TipRanks · 5d ago
More
Webull provides a variety of real-time DVA stock news. You can receive the latest news about Davita Inc through multiple platforms. This information may help you make smarter investment decisions.
About DVA
DaVita Inc. is a healthcare provider focused on transforming care delivery to improve the quality of life for patients globally. The Company is a provider of kidney care services in the United States. Its United States dialysis (U.S. dialysis) and related lab services business treats patients with chronic kidney failure and end-stage kidney disease (ESKD). The Company’s robust platform delivers kidney care services and includes established nephrology and payor relationships. The Company’s international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company’s U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. It also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations.